PeptiGrowth Inc Presentation: Synthetic Peptide Growth Factors: Bringing innovation to Cell Therapy and Regenerative Medicine
Wednesday, May 29, 2024 07:15 PM - 07:30 PM
Exhibit Hall - Theatre A
Global Showcase Presentation
Presenter(s)
Conventional growth factors (GFs) used in the manufacturing of regenerative medicine and cell therapy products face various challenges, such as lot-to-lot quality variations, potential contamination with biological impurities, low stability, and high manufacturing costs. Leveraging the technology called Peptide Discovery Platform Systems (PDPS), PeptiGrowth Inc. has been working on developing a series of synthetic peptides that possess the same activities and functions as conventional GFs. These peptides can address and overcome all these challenges. They are entirely chemically synthesized and free from animal components, making them suitable for all cell culturing applications. Currently, eight peptides have been developed, including HGF alternative peptide, TGF-β1 inhibitor, BDNF alternative peptide, Noggin-like peptide, BMP7 selective inhibitor, BMP4 selective inhibitor, VEGF alternative peptide, and Wnt3a alternative peptide. This presentation will share an overview of the PDPS system, experiences gained from denovo synthetic peptide growth factor discovery and data from the application of these peptide growth-factors.
Session Objectives:
• How synthetic peptide growth factors are created and work
• Benefits of using synthetic peptide growth factors in cell therapy and regenerative medicine
• Functional properties and application data of synthetic peptide growth factors
- Jes Kuruvilla, Business Development Manager, Mitsubishi International Food Ingredients, Inc., USA
Conventional growth factors (GFs) used in the manufacturing of regenerative medicine and cell therapy products face various challenges, such as lot-to-lot quality variations, potential contamination with biological impurities, low stability, and high manufacturing costs. Leveraging the technology called Peptide Discovery Platform Systems (PDPS), PeptiGrowth Inc. has been working on developing a series of synthetic peptides that possess the same activities and functions as conventional GFs. These peptides can address and overcome all these challenges. They are entirely chemically synthesized and free from animal components, making them suitable for all cell culturing applications. Currently, eight peptides have been developed, including HGF alternative peptide, TGF-β1 inhibitor, BDNF alternative peptide, Noggin-like peptide, BMP7 selective inhibitor, BMP4 selective inhibitor, VEGF alternative peptide, and Wnt3a alternative peptide. This presentation will share an overview of the PDPS system, experiences gained from denovo synthetic peptide growth factor discovery and data from the application of these peptide growth-factors.
Session Objectives:
• How synthetic peptide growth factors are created and work
• Benefits of using synthetic peptide growth factors in cell therapy and regenerative medicine
• Functional properties and application data of synthetic peptide growth factors
SPONSORED BY:
No Speakers Found.